Bicara Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BCAX Nasdaq 2834 www.bicara.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bicara Therapeutics Inc.

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Jul 8th, 2025 10:55 pm
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Jun 11th, 2025 2:05 pm
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Jun 3rd, 2025 2:01 pm
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - Jun 1st, 2025 11:12 am
ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer - May 29th, 2025 4:54 am
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - May 27th, 2025 11:59 am
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - May 26th, 2025 7:14 am
Sector Update: Health Care Stocks Decline Late Afternoon - May 23rd, 2025 1:56 pm
Top Midday Decliners - May 23rd, 2025 11:49 am
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - May 23rd, 2025 8:15 am
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting - May 22nd, 2025 3:00 pm
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - May 13th, 2025 5:30 am
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - Apr 28th, 2025 2:01 pm
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 23rd, 2025 8:00 am
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 27th, 2025 5:30 am
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - Mar 25th, 2025 2:45 pm
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Mar 12th, 2025 4:44 am
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Feb 24th, 2025 2:01 pm
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Feb 11th, 2025 2:01 pm
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium - Jan 27th, 2025 6:00 am